Perrigo Company plc Proceeds from Royalties Received
Perrigo Company plc (PRGO) reported Proceeds from Royalties Received of $2.90 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRoyaltiesReceived · last filed 2020-02-27
- Perrigo Company plc proceeds from royalties received for the quarter ending 2019-12-31 was $700.00K, a 69.57% decline year-over-year.
- Perrigo Company plc proceeds from royalties received for the quarter ending 2019-09-28 was $500.00K, a 54.55% decline year-over-year.
- Perrigo Company plc proceeds from royalties received for the quarter ending 2019-06-29 was $500.00K, a 66.67% increase year-over-year.
- Perrigo Company plc proceeds from royalties received for the quarter ending 2019-03-30 was $1.20M, a 88.00% decline year-over-year.
- Perrigo Company plc proceeds from royalties received for fiscal 2019 was $2.90M, a 78.83% decline from fiscal 2018.
- Perrigo Company plc proceeds from royalties received for fiscal 2018 was $13.70M, a 84.31% decline from fiscal 2017.
- Perrigo Company plc proceeds from royalties received for fiscal 2017 was $87.30M, a 75.32% decline from fiscal 2016.
- Perrigo Company plc proceeds from royalties received for fiscal 2016 was $353.70M.
| Period end | Proceeds from Royalties Received 3 month | Proceeds from Royalties Received 6 month | Proceeds from Royalties Received 9 month | Proceeds from Royalties Received 12 month |
|---|---|---|---|---|
| 2019-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.20M derived: sum of 2 quarters · filed 2020-02-27 | $1.70M derived: sum of 3 quarters · filed 2020-02-27 | $2.90M 10-K · filed 2020-02-27 |
| 2019-09-28 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $1.00M derived: sum of 2 quarters · filed 2019-11-06 | $2.20M 10-Q · filed 2019-11-06 | $4.50M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-29 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.70M 10-Q · filed 2019-08-08 | $4.00M derived: sum of 3 quarters · filed 2020-02-27 | $5.10M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-30 | $1.20M 10-Q · filed 2019-05-09 | $3.50M derived: sum of 2 quarters · filed 2020-02-27 | $4.60M derived: sum of 3 quarters · filed 2020-02-27 | $4.90M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $3.40M derived: sum of 2 quarters · filed 2020-02-27 | $3.70M derived: sum of 3 quarters · filed 2020-02-27 | $13.70M 10-K · filed 2020-02-27 |
| 2018-09-29 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $1.40M derived: sum of 2 quarters · filed 2019-11-06 | $11.40M 10-Q · filed 2019-11-06 | $12.30M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $10.30M 10-Q · filed 2019-08-08 | $11.20M derived: sum of 3 quarters · filed 2020-02-27 | $11.90M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $10.00M 10-Q · filed 2019-05-09 | $10.90M derived: sum of 2 quarters · filed 2020-02-27 | $11.60M derived: sum of 3 quarters · filed 2020-02-27 | $12.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.60M derived: sum of 2 quarters · filed 2020-02-27 | $2.00M derived: sum of 3 quarters · filed 2020-02-27 | $87.30M 10-K · filed 2020-02-27 |
| 2017-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.10M derived: sum of 2 quarters · filed 2018-11-08 | $86.40M 10-Q · filed 2018-11-08 | $180.60M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-07-01 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $85.70M 10-Q · filed 2018-08-09 | $179.90M derived: sum of 3 quarters · filed 2019-02-27 | $269.50M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-04-01 | $85.30M 10-Q · filed 2018-05-08 | $179.50M derived: sum of 2 quarters · filed 2019-02-27 | $269.10M derived: sum of 3 quarters · filed 2019-02-27 | $355.60M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $94.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $183.80M derived: sum of 2 quarters · filed 2019-02-27 | $270.30M derived: sum of 3 quarters · filed 2019-02-27 | $353.70M 10-K · filed 2019-02-27 |
| 2016-10-01 | $89.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $176.10M derived: sum of 2 quarters · filed 2017-11-09 | $259.50M 10-Q · filed 2017-11-09 | |
| 2016-07-02 | $86.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $169.90M 10-Q · filed 2017-08-10 | ||
| 2016-04-02 | $83.40M 10-Q · filed 2017-05-30 | |||
| 2015-12-31 | $166.30M 10-K · filed 2018-03-01 | |||
| 2015-09-26 | $81.40M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-05-23 | $162.50M derived: sum of 2 quarters · filed 2017-05-23 | $250.30M 10-Q/A · filed 2017-05-23 | |
| 2015-06-27 | $81.10M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | $168.90M 10-Q/A · filed 2017-05-22 | $344.60M 10-K · filed 2018-03-01 | |
| 2015-03-28 | $87.80M 10-Q/A · filed 2017-05-22 | |||
| 2014-06-28 | $60.50M 10-K · filed 2017-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |